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Abstract (299 words) 57 
Background  Cariprazine is a novel antipsychotic agent recently approved for treating 58 
schizophrenia and bipolar mania in the US. Sample sizes of published randomized 59 
controlled trials (RCTs) of the drug are small; previous meta-analyses included few 60 
RCTs and did not specifically investigate the tolerability/safety profile of cariprazine. 61 
Objective  A meta-analysis of published RCTs was conducted to systematically review 62 
the tolerability and safety of cariprazine versus placebo.  63 
Methods  Clinical trials registers (the metaRegister of controlled trials, the Clinical trials 64 
government and the World Health Organisation International Clinical Trials Registry 65 
Platform) and electronic databases (PubMed, Embase, PsycINFO and Cochrane library) 66 
were searched up to June 2016 to identify phase II/III RCTs of cariprazine in patients 67 
with schizophrenia, bipolar disorder or major depressive disorder. A meta-analysis was 68 
conducted to investigate outcomes, including risks of discontinuation due to adverse 69 
events (AEs), extrapyramidal side effects (EPS) or related events, metabolic syndrome 70 
and cardiovascular-related events.  71 
Results  Nine RCTs were included with a total of 4,324 subjects. The risk of 72 
discontinuation due to AEs for cariprazine was similar to placebo (risk ratio [RR] =1.13, 73 
95% confidence interval [95%CI] 0.77-1.66). Cariprazine was associated with higher 74 
risks of EPS-related events compared to placebo, including risk of akathisia (RR=3.92, 75 
95%CI 2.83-5.43), tremor (RR=2.41, 95%CI 1.53-3.79) and restlessness (RR=2.17, 76 
95%CI 1.38-3.40). The cariprazine treatment group was more likely to have clinically 77 
significant weight gain (RR=1.68, 95%CI 1.12-2.52). No statistically significant 78 
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differences in results were found in other metabolic parameters or cardiovascular-79 
related events. 80 
Conclusion  There was a statistically significant higher risk of EPS-related adverse 81 
events and a slight increase in mean body weight with cariprazine. There were no 82 
statistically significant effects on prolactin level or cardiovascular parameters. EPS 83 
were the main short-term adverse reactions reported in the limited number of patients 84 
studied. Further clinical and post-marketing pharmacovigilance studies are needed to 85 
investigate the long-term safety of cariprazine. 86 
  87 
Page 6 of 33 
 
1. Introduction 88 
Antipsychotic drugs (APDs) have been the mainstay for the management of 89 
schizophrenia for more than 60 years [1]. In recent decades they have also become 90 
established in the treatment of bipolar disorder, for episodes of both mania and 91 
depression [2], and were also recommended as combination treatment with 92 
antidepressants for major depressive disorder (MDD) [3]. Dopamine D2 receptor 93 
antagonism appears to be a key mechanism in the efficacy of APDs [4]. Second 94 
generation antipsychotics (SGAs) also have affinity to other receptors, including but 95 
not limited to, dopamine (other than D2), serotonin, muscarinic, cholinergic and 96 
histamine receptors [5]. The affinity to multiple receptors was thought to contribute to 97 
better efficacy and lower risk of extrapyramidal side effects (EPS) and tardive 98 
dyskinesia compared to first generation antipsychotics [6]. However, the claims of 99 
better efficacy have been questioned and, although SGAs are associated with less EPS, 100 
they have been shown to be associated with higher risks of weight gain [7], metabolic 101 
syndrome (including dyslipidemia, hyperglycemia) [8-10], arrhythmia [11] and 102 
hyperprolactinemia [12]. Drug-induced adverse events are the major cause of APD 103 
discontinuation [12]. It is consequently important for prescribing clinicians to have 104 
sound knowledge of the tolerability/safety profile of APDs and closely monitor patients 105 
on APD treatment. 106 
Cariprazine (VraylarTM, also previously known as RG-188 or trans-4-(2-(4-(2,3-107 
dichlorophenyl)piperazine-1-yl)-ethyl)-N,N-dimethylcarbamoyl-cyclohexyl-amine 108 
hydrochloride) is a new APD approved by the U.S. Food and Drug Administration 109 
(FDA) to treat schizophrenia and bipolar mania in adults on September 17, 2015 [13]. 110 
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Data on efficacy, tolerability and safety in adult patients with acute exacerbations of 111 
schizophrenia [14-17], acute or mixed mania associated with bipolar I disorder [18-20], 112 
bipolar I depression [21] and MDD [22] have been reported in phase II and III RCTs. 113 
Compared with placebo, superiority in efficacy and general tolerability of cariprazine 114 
has been demonstrated in these RCTs. With regard to safety, the sample sizes of these 115 
RCTs are not adequate to provide definitive data.  116 
As a dopamine D2 and D3 receptors partial agonist, cariprazine has preference for D3 117 
receptors [23, 24]. Its high affinity to D3 receptor has been shown both in vitro and in 118 
vivo [23, 24]. In contrast, D3 receptor occupancy is low or negligible with other SGAs, 119 
as reported in positron emission tomography studies [25-27]. With regard to other 120 
receptors, cariprazine shows partial agonism at 5-HT1A receptors and acts as an 121 
antagonist of 5-HT2B receptors with high affinity, and low affinity for 5-HT2A, 5-HT2C, 122 
adrenergic α1 and histamine H1 receptors [24]. In animal studies, cariprazine has been 123 
shown to have antipsychotic-like activity, including (but not limited to) inhibition of 124 
amphetamine-induced climbing and hyperactivity in vivo [23]. Based on the 125 
pharmacological actions, a distinct tolerability/safety profile from other marketed 126 
SGAs might be anticipated. 127 
Previous cariprazine meta-analyses or post-hoc analyses have focused on efficacy [28-128 
32] but did not investigate its tolerability and safety. Due to its unique pharmacological 129 
profile, there is a need for a systematic review of the tolerability/safety data of 130 
cariprazine. The objective of this study was to investigate the tolerability/safety 131 
outcomes of cariprazine compared to placebo in adult patients with schizophrenia, 132 
bipolar mania, bipolar depression and MDD from phase II/III RCTs through a meta-133 
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analysis. 134 
2. Methods 135 
This systematic review was conducted following guidance provided in the Cochrane 136 
Handbook [33] and is reported in accordance with the Preferred Reporting Items for 137 
Systematic reviews and Meta-Analyses (PRISMA) [34]. The protocol for the meta-138 
analysis will be provided at http://www.pharma.hku.hk/sweb/CSMPR/.  139 
2.1.Study population 140 
The study population included adult patients (aged 18 years old and above) in phase 141 
II/III RCTs allocated to cariprazine (treatment group) or placebo for the management 142 
of any mental disorder. Details of outcome measures are provided in section 2.5. 143 
2.2.Data sources and search strategy 144 
A literature search for any RCTs of cariprazine was performed using PubMed, Embase, 145 
PsycINFO, the Cochrane library and trial registries including the metaRegister of 146 
controlled trials (www.controlled-trials.com), the Clinical trials government 147 
(http://www.ClinicalTrials.gov) and the World Health Organisation International 148 
Clinical Trials Registry Platform (ICTRP) (http://www.who.int/ictrp/en/). The latest 149 
search was conducted on 13th June 2016. The search strategy was “Vraylar OR (trans-150 
4-(2-(4-(2,3-dichlorophenyl)piperazine-1-yl)-ethyl)-N,N-dimethylcarbamoyl-151 
cyclohexyl-amine) OR RGH-188 OR cariprazine”. No restrictions were set on 152 
publication time, study size, treatment duration or language. Duplicates were removed. 153 
Titles, abstracts and full texts were screened to determine whether the studies met the 154 
inclusion/exclusion criteria. The bibliographies of relevant review articles were also 155 
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screened to identify any potentially relevant studies.  156 
2.3. Inclusion and exclusion criteria 157 
Published randomized, placebo-controlled phase II and III trials investigating the  158 
tolerability and safety of cariprazine in patients with mental disorders were eligible. 159 
Full texts were evaluated for assessing the inclusion criteria. Conference abstracts were 160 
excluded due to the unknown quality of studies. Studies without double-blind design 161 
applied were excluded due to unknown risk of bias.  162 
2.4.Evaluation of bias 163 
The methodological quality of included RCTs was assessed using the Cochrane 164 
Collaboration tool for assessing the risk of bias [35]. Assessment was conducted and 165 
cross-checked by two independent reviewers (KSJL and YH). Any discrepancies were 166 
addressed by re-evaluation and discussion to reach consensus. The Grading of 167 
Recommendations Assessment, Development, and Evaluation (GRADE) guidelines 168 
were applied to assess the quality of a body of evidence [36, 37]. Evidence profile table 169 
and summary of findings table were generated using GRADEpro [38]. 170 
2.5.Outcome measures 171 
The primary outcomes for assessing tolerability/safety were (1) discontinuation due to 172 
adverse events (AEs), (2) EPS related outcomes, (3) metabolic syndrome related 173 
outcomes, and (4) cardiovascular adverse effects related outcomes. Details of the risks 174 
of discontinuation, treatment-emergent adverse effects (TEAEs), use of rescue 175 
medication and mean changes of laboratory parameters analysed in the four categories 176 
are described and defined below. A TEAE was defined as an adverse event that 177 
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occurred or deteriorated during the treatment period. 178 
(1) Discontinuation due to total AEs. 179 
(2) EPS outcomes: akathisia, tremor and restlessness, reported as adverse events during 180 
treatment period; treatment-emergent akathisia (based on a Barnes Akathisia Rating 181 
Scale, BARS score ≤2 at baseline and >2 after baseline); treatment-emergent 182 
Parkinsonism (based on a Simpson-Angus Scale, SAS score ≤3 at baseline and >3 after 183 
baseline); and use of anti-Parkinson medication or beta-blockers. 184 
(3) Metabolic outcomes: potential clinically significant (PCS) changes in weight 185 
(defined as 7% weight gain) from baseline in original studies [14, 16-21]) and PCS 186 
changes in fasting glucose (defined as a shift from normal glucose levels (<100 mg/dL) 187 
at baseline to high glucose levels (≥126 mg/dL) at the end of treatment [18, 19, 21]). In 188 
addition, all changes in body weight (from baseline to the end of treatment), total 189 
cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), 190 
triglycerides and prolactin were pooled and reported, where available. 191 
 (4) Cardiovascular outcomes: orthostatic hypotension (defined as ≥20 mmHg systolic 192 
or ≥10 mmHg diastolic reduction in blood pressure from supine to standing position 193 
[14, 18, 21]), blood pressure, and creatine kinase levels. In addition, as important 194 
parameters of cardiovascular outcomes, changes in QTcB (QT interval, Bazett’s 195 
formula corrected) were also reviewed narratively as data was unavailable for meta-196 
analysis.  197 
Secondary outcomes included other individual types of TEAEs, serious adverse events 198 
(SAEs), laboratory parameters of liver function and vital signs. The term SAE was used 199 
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in all included RCTs but not explicitly defined. In addition, discontinuations due to 200 
other causes were analysed. 201 
2.6.Data extraction 202 
The initial literature search and screening for eligible RCTs were independently 203 
performed by two researchers (KSJL and YH). Primary and secondary outcome data 204 
were also extracted from included RCTs by both reviewers independently and cross-205 
checked for accuracy. Data not used in the statistical analyses including characteristics 206 
of studies and patients were extracted and summarized. 207 
2.7.Statistical methods 208 
The Mantel-Haenszel method [39, 40] with random effects model [41] was used to 209 
calculate the risk ratios (RRs) for all dichotomous outcomes (adverse events, PCS 210 
changes of scales or parameters). Laboratory parameters were analysed as continuous 211 
data. The inverse variance method with random effects model was used to estimate the 212 
pooled mean difference of continuous outcomes from baseline to the end of treatment 213 
[41]. Standardized mean difference (SMD) was calculated for continuous outcomes to 214 
compare with results from other meta-analyses investigating safety profiles of APDs. 215 
For the calculation of SMD, the difference in mean outcomes between groups was 216 
divided by the standard deviation of outcomes among studies. Heterogeneity was 217 
assessed using Cochran’s Q statistics, I2 statistics and prediction intervals. Cochran’s 218 
Q statistical test was considered statistically significant when P <0.10 [42]. The I2 219 
statistic was also calculated to estimate the proportion of total variation among studies, 220 
where values of 25%, 50% and 75% were regarded as low, moderate and high 221 
heterogeneity, retrospectively [43]. 95% prediction intervals (95%PI) were calculated 222 
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for primary outcomes reported in at least 5 RCTs by using tau-squared [44]. Range and 223 
width of 95%PI reflect heterogeneity [45, 46].  224 
Review Manager 5.3 [47] was used to conduct all statistical analyses. P-values (two-225 
tailed) <0.05 were regarded as statistically significant, except for heterogeneity tests. 226 
Online module (statstodo.com) was used to combine means and standard deviations of 227 
continuous variables from multiple groups [48]. 228 
2.8.Subgroup and sensitivity analyses 229 
Subgroup analyses of the nine included RCTs were conducted based on different 230 
indications of cariprazine use and various doses of cariprazine. Subgroup analyses were 231 
performed to investigate the source of heterogeneity in assessing primary outcomes. 232 
All primary outcomes were analysed in subgroups. Results were compared with those 233 
of the main analysis, where all cariprazine users belong to one treatment group. Results 234 
were also compared between subgroups. Subgroup analysis (by indication) was 235 
conducted for indications including schizophrenia and manic episodes of bipolar 236 
disorder. Subgroup analysis by dose was stratified by cariprazine dose (low dose group 237 
was defined as dose 6mg/day or below and high dose group was defined as above 238 
6mg/day, based on the treatment dose range recommended by the FDA [49]).  239 
The treatment intervention in one of the included RCTs was a combination of 240 
cariprazine and  antidepressant [22], while in the other eight RCTs it was cariprazine 241 
alone. Hence a post-hoc sensitivity analysis was conducted where this study was 242 
excluded in the primary analysis to investigate the impact of the adjunctive 243 
antidepressant on the outcomes of interest in this study. 244 
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3. Results 245 
3.1.Search results 246 
Figure 1 summarizes the review flowchart in accordance with the PRISMA statement. 247 
The search of electronic databases including PubMed, Embase, PsycINFO and 248 
Cochrane library yielded a total of 563 studies. Twenty-two records were found 249 
registered at clinicaltrial.gov and 41 at ICTRP. After removing duplicates and screening 250 
abstracts, 29 full-texts were further assessed for eligibility. Overall nine RCTs met the 251 
inclusion criteria and were included in the systematic review. 252 
3.2.Characteristics and quality of included RCTs 253 
 Table 1 summarizes the characteristics of included studies. Of the nine RCTs included, 254 
four [14-17] investigated the use of cariprazine in patients with schizophrenia, three 255 
[18-20] investigated the use of cariprazine in mania associated with bipolar I disorder, 256 
one [21] focused on patients with bipolar I depression and one recruited patients with 257 
MDD [22]. Treatment duration ranged from three to eight weeks. Daily cariprazine 258 
doses investigated in these RCTs ranged from 0.75 mg to 12 mg. Antidepressants 259 
(including but not limited to sertraline, citalopram, escitalopram, venlafaxine and 260 
duloxetine) were used in combination with placebo or cariprazine in one RCT [22]. 261 
The included RCTs were rated as “low risk of bias” or “unclear” with respect to 262 
sequence generation, allocation concealment, blinding setting and outcome data 263 
reporting (Supplementary Table 1). As reported in the evidence profile table 264 
(Supplementary Table 2) and the summary of findings table (Supplementary Table 265 
3), with the exception of the  outcomes of discontinuation due to AEs and use of anti-266 
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Parkinson medication being rated as “Low”, the quality of a body of evidence for 267 
primary outcomes were rated as “High” or “Moderate”.  268 
3.3.Discontinuation of treatment 269 
There was no statistically significant difference between discontinuation due to AEs in 270 
the cariprazine treatment group compared to the placebo group, RR 1.13 (95%CI 0.77-271 
1.66, 95%PI 0.32-3.93) (Figure 2).  272 
3.4.Extrapyramidal symptoms (EPS) 273 
Discontinuation due to EPS-related TEAEs was more likely in the cariprazine group 274 
(RR 3.31, 95%CI 1.06-10.32, 95%PI 0.52-21.00) (Table 2). Cariprazine-treated 275 
patients had greater than a 3-fold increase in the  risk than placebo-treated patients of 276 
treatment-emergent Parkinsonism (RR 3.33, 95%CI 2.17-5.13, 95%PI 1.34-8.27) and 277 
treatment-emergent akathisia (RR 3.36, 95%CI 2.48-4.56, 95%PI 1.69-6.67), defined 278 
as change of SAS (≤3 at baseline and >3 after baseline) and BARS (≤2 at baseline 279 
and >2 after baseline) respectively (Figure 2). Similarly, the cariprazine-treated group 280 
was more likely to receive anti-Parkinson medication (RR 2.79, 95%CI 2.04-6.73, 281 
95%PI 0.35-22.18) and beta-blocking medication (RR 3.71, 95%CI 2.04-6.73, 95%PI 282 
not applicable) for treating akathisia (Figure 2). Cariprazine-treated patients had a 283 
higher risk of EPS-related AEs including akathisia (RR 3.92, 95%CI 2.83-5.43, 95%PI 284 
2.12-7.25), tremor (RR 2.41, 95%CI 1.52-3.79, 95%PI 1.01-5.75) and restlessness (RR 285 
2.17, 95%CI 1.38-3.40, 95%PI 0.85-5.54) (Table 2). There was a statistically 286 
significant increase in the mean change in BARS scale (for akathisia) and SAS scale 287 
(for Parkinsonism) as shown in Table 2. 288 
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3.5.Metabolic outcomes 289 
From the eight RCTs which had reported the PCS change in weight, the meta-analysis 290 
showed that the cariprazine group were more likely to have a clinically significant 291 
weight gain compared to the placebo group (RR 1.68, 95%CI 1.12-2.52, 95%PI 1.01-292 
2.79) (Figure 2). Furthermore, the cariprazine-treated group had an increased mean 293 
weight of 0.61kg (95%CI 0.39-0.82, 95%PI 0.02-1.20) compared to the placebo group 294 
(Table 2). There was no PCS change in fasting glucose (glucose levels less than 100 295 
mg/dL at baseline to 126 mg/dL or above at the end of treatment). In addition, there 296 
was no statistically significant difference between the cariprazine and placebo groups 297 
in the mean change from baseline to the end of treatment of total cholesterol, LDL, 298 
HDL, triglycerides, prolactin and fasting glucose.  299 
The mean change in body weight for cariprazine was statistically significantly lower 300 
(mean change -0.73 kg, 95%CI -1.34 to -0.13) than for risperidone [16]. In the study 301 
with the aripiprazole arm as an active control, mean change in fasting glucose in the 302 
cariprazine group was statistically significantly elevated compared with aripiprazole 303 
(mean difference 4.21 mg/dL, 95%CI 1.24-7.17), however this was not statistically 304 
different from the placebo group (mean difference -1.59 mg/dL, 95%CI -8.01 to 4.83) 305 
[17]. 306 
3.6.Cardiovascular outcomes 307 
The risk of orthostatic hypotension was similar between cariprazine and placebo groups. 308 
Both systolic and diastolic blood pressure were marginally higher in cariprazine group 309 
(Table 2). The mean creatine kinase level was higher in the cariprazine group compared 310 
to placebo, with a statistically significant difference of 17.49 U/L (95%CI 1.63-33.35, 311 
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95%PI -17.33 to 52.31). Data was inadequate for QTc intervals and hence was not 312 
included in meta-analysis; however three adverse events of QTcB interval >500 msec 313 
were reported in two RCTs (two in the placebo group and one in the cariprazine-treated 314 
group) [18, 20]. 315 
3.7.Secondary outcomes 316 
Three deaths were reported in the cariprazine-treated group from two RCTs [17, 20] 317 
and no death was reported in the placebo group. Meta-analysis of other 318 
tolerability/safety outcomes, including risks of other reasons for discontinuation, risks 319 
of specific AEs and SAEs, mean change in parameters for liver function, vital signs, 320 
suicidal ideation defined by Columbia-Suicide Severity Rating Scale (C-SSRS) and use 321 
of benzodiazepines mostly yielded statistically non-significant differences between the 322 
cariprazine and placebo groups. Detailed results are presented in the Supplementary 323 
Table 4. There was a lower risk of total SAEs (RR 0.62, 95%CI 0.42-0.91) in the 324 
cariprazine group compared to the placebo group. However, the following AEs were 325 
more frequently reported in the cariprazine group than in the placebo group, with 326 
statistically significant results: nausea, extrapyramidal disorder, vomiting, constipation, 327 
dizziness, somnolence and blurred vision (Supplementary Table 4). Forest plots for 328 
all outcomes were shown in Supplementary Figure 1. 329 
3.8.Subgroup and sensitivity analyses 330 
In the subgroup analysis stratified by dose, most of the results were similar/consistent 331 
with the main analysis, with the exception of the risk ratios of PCS weight change in 332 
high-dose group (>6mg/day) did not reach statistical significance (Supplementary 333 
Table 5). In comparisons between subgroups, the mean change in the SAS scale was 334 
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larger in the high-dose group compared to the low-dose group (Supplementary Table 335 
5). 336 
When stratifying by indication, cariprazine was associated with a statistically 337 
significant higher risk of PCS weight change in patients with schizophrenia; however, 338 
it did not reach statistical significance in patients with bipolar mania disorder 339 
(Supplementary Table 6). The mean change in SAS scale between the cariprazine and 340 
placebo groups was statistically significantly higher in bipolar mania patients compared 341 
with patients with schizophrenia (Supplementary Table 6). 342 
Sensitivity analysis showed similar results to the primary analysis except the mean 343 
change of LDL level was marginally lower in cariprazine group with statistically 344 
significant difference (-2.11 mg/dL, 95%CI -4.09, -0.13), while in the primary analysis, 345 
no statistically significant difference was detected. 346 
 347 
4. Discussion 348 
To our knowledge this is the first systematic review and meta-analysis to investigate 349 
tolerability and safety of cariprazine by combining all available RCTs to date. This 350 
review provides a comprehensive and evidence-based overview of the 351 
tolerability/safety profiles of cariprazine used for different indications including 352 
schizophrenia, bipolar mania, bipolar depression and MDD. 353 
Our results should be interpreted with caution as the treatment periods were relatively 354 
short (three to eight weeks) and long-term safety data was not reported. An RCT with 355 
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a 6-month treatment period was conducted; however this study was excluded as it was 356 
not placebo-controlled [50]. Patients in the treatment arms received daily doses similar 357 
to the recommended doses in the manufacturer’s product information (1.5–6 mg/d for 358 
schizophrenia and 3–6 mg/d for bipolar mania [49]) or doses higher than recommended. 359 
Notably, the included patients were relatively young (average age approximately 40 360 
years). Whether similar results will be seen in older or younger patients remains to be 361 
explored as extensive data on these age groups are currently not available. The number 362 
of available RCTs was limited: only nine RCTs were included in our study. Some of 363 
the outcomes were not consistently reported in all the RCTs. Therefore results presented 364 
in this study should be interpreted with caution as it may not be adequately powered. 365 
Discontinuation of treatment is a composite outcome measure of tolerability/safety and 366 
efficacy. There was no statistically significant difference in the all-cause 367 
discontinuation of cariprazine treatment compared to placebo. This suggests that the 368 
tolerability of cariprazine was generally good. Additional analysis of the data on 369 
discontinuation due to AEs and SAEs (Tables 2 and supplementary table 4) did not 370 
reveal statistically significant differences between cariprazine and placebo, also 371 
suggesting that cariprazine was well tolerated by the patients. However, the meta-372 
analysis is not adequately powered to detect a difference in some of the individual 373 
adverse effects between cariprazine and placebo. There were more patients in the 374 
placebo group who discontinued treatment due to insufficient drug response, which 375 
indirectly suggests superior efficacy of cariprazine when compared to placebo. This 376 
result is consistent with results of previous RCTs and meta-analyses suggesting better 377 
efficacy of cariprazine compared to placebo [29-31].  However, additional RCTs are 378 
required for adequate power to detect a difference in tolerability and safety outcomes 379 
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between cariprazine and placebo. 380 
As with some of the other SGAs, akathisia was a common TEAE. Statistically 381 
significant higher risks of EPS-related TEAEs, including akathisia, tremor, restlessness 382 
and overall extrapyramidal disorder were reported in the cariprazine than in the placebo 383 
group. The use of rescue medications is also an indicator reflecting clinically significant 384 
EPS-related events. The odds ratios (ORs) versus placebo of at least one occasion of 385 
the prescription of anti-Parkinson drugs for other marketed antipsychotics in the study 386 
by Leucht et al. varied from 0.3 (clozapine, 95%CI 0.12-0.62) to 4.76 (haloperidol, 387 
95%CI 3.70-6.04) [51]. The result in our analysis (OR 3.49, 95%CI 1.91-6.38) 388 
overlapped with the range reported by Leucht et al. [51]. Pooled risk ratios of treatment-389 
emergent akathisia, defined by BARS was 3.36 (95%CI 2.48-4.56), which was similar 390 
to the results for other SGAs (RR 5.37, 95%CI 3.38-8.53), as reported in previous meta-391 
analyses [52, 53]. The available data indicate that cariprazine is consistently associated 392 
with a higher risk of EPS compared to placebo. Although cariprazine has a different 393 
pharmacological profile from other SGAs, the risk of EPS appears to be similar. 394 
Although there was a statistically significant difference between cariprazine and 395 
placebo in several of the outcomes (e.g. discontinuation due to akathisia, risk of tremor, 396 
risk of restlessness, mean change in BARS, SAS and AIMS scores in Table 2), the 397 
results should still be interpreted with caution, as the analysis may have been 398 
underpowered for some of the other outcomes due to the small number of 399 
studies/patients included. 400 
Our analysis revealed that cariprazine was associated with a marginally increased risk 401 
of PCS weight gain compared with placebo. The pooled mean change of body weight 402 
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was only 0.61 kg (standard mean difference=0.25, 95%CI 0.17-0.34) during the study 403 
period. However, it should be noted that this is a mean result and does not indicate 404 
whether some individuals gained weight excessively nor do these relatively brief 405 
studies give any indication of the long-term effects on weight or other adverse effects. 406 
Compared to the standardized mean difference in weight gain or risk reduction in PCS 407 
weight gain of other SGAs, cariprazine was associated with less mean weight gain than 408 
olanzapine, quetiapine, risperidone and clozapine [51, 52], with similar risk of PCS 409 
weight gain as aripiprazole and ziprasidone [51-53]. Weight gain, hyperglycaemia and 410 
dyslipidaemia (elevated total cholesterol and LDL, and decreased HDL level) are the 411 
main risk factors contributing to cardiovascular diseases in patients with schizophrenia 412 
and can be frequently observed in users of SGAs [54]. In our results, levels of total 413 
cholesterol, LDL and HDL did not differ statistically significantly between the placebo 414 
and cariprazine groups – generally this shows a more favourable metabolic profile than 415 
other SGAs. No statistically significant elevation of prolactin level was revealed in our 416 
analysis. 417 
In summary the cariprazine-treated group had a PCS change in weight but the overall 418 
magnitude of changes of metabolic parameters was mild or benign and in these short-419 
term RCTs. However, these results should be interpreted in the light of the relatively 420 
short treatment period, as some of the metabolic problems may take time to become 421 
established. 422 
Cariprazine was associated with a statistically significant but mild elevation of creatine 423 
kinase. However, no acute myocardial infarction was reported and this result appears 424 
unlikely to be clinically significant. Marginally statistical significant changes in blood 425 
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pressure were observed, however there was no difference in reports of orthostatic 426 
hypotension between cariprazine and placebo. No cardiovascular safety concerns were 427 
reported in the short periods of treatment. QTcB prolongation remains to be further 428 
explored. Again, data on long-term drug use in large numbers of patients are needed to 429 
provide a complete evaluation of the cardiovascular safety profile. 430 
Using a 6mg/day cut-off, seven of the nine RCTs had a low-dose cariprazine treatment 431 
group and four of nine RCTs had a high-dose cariprazine treatment group. Although 432 
results of subgroup analysis are not statistically significant, no conclusion regarding the 433 
dose response relationship can be drawn with the limited published data available. 434 
Further studies are required to confirm the dose response. 435 
Among the nine included RCTs, an active-control design was used in two studies where 436 
cariprazine was also compared with risperidone and aripiprazole, respectively [16, 17]. 437 
However, the sample sizes of direct comparison with active comparators were too 438 
limited to allow conclusions to be drawn. Another RCT where cariprazine was 439 
compared with risperidone [50] was excluded as there was no placebo arm. Future 440 
studies are needed for comparative safety. However, as some of the outcomes were not 441 
reported in all nine RCTs, results should be interpreted with caution due to the small 442 
sample size. 443 
5. Conclusions 444 
Our meta-analysis of short-term RCTs suggested that cariprazine was generally well 445 
tolerated, as indicated by similar discontinuation rates due to adverse events between 446 
drug and placebo groups. Cariprazine was associated with a higher risk of EPS-related 447 
Page 22 of 33 
 
adverse events, particularly akathisia, and a slight increase in mean body weight. No 448 
statistically significant effects on prolactin level or the cardiovascular system were 449 
evident. It is important that patients are informed of the potential EPS. More clinical 450 
and post-marketing pharmacovigilance studies are needed to investigate the long-term 451 
tolerability and safety of cariprazine.  452 
 453 
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 454 
Figure 1 PRISMA flowchart summarizing study identification and selection455 
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Figure 2 Forest plots of primary safety outcomes: (A) discontinuation due to AEs; (B) potential clinically significant change in weight; (C) risks of 456 
treatment-emergent extrapyramidal side effects and (D) use of rescue medication for extrapyramidal side effects. 457 
 458 
Abbreviations: EPS, extrapyramidal side effects; PCS, potential clinically significant. 459 
Tau-squared statistics were used to calculate prediction intervals (by default as generated by RevMan). 460 
*PCS change in weight was defined as a 7% weight gain from baseline.  461 
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Table 1 Characteristics of randomized controlled studies included in this meta-analysis 462 
Article Region Study design Indication 
Treatment 
Duration 
(weeks) 
Intervention, (dose, 
[mg/d]) 
Number of 
patients (safety 
population) 
Male Age (years) 
n % mean SD 
Calabrese 
2015 [20] 
U.S, Romania, 
Russia, Croatia, 
Ukraine & 
Serbia 
Double-blind, 
placebo-controlled bipolar I mania 3 
placebo 161 89 55.3 41.5 11.4 
cariprazine (3-6) 167 90 53.9 43.1 12.2 
cariprazine (6-12) 169 85 50.3 41.2 11.3 
Durgam 
2014 [16] 
U.S, India, 
Russia, Ukraine 
& Malaysia 
Double-blind, 
placebo- and 
active-controlled 
schizophrenia 6 
placebo 151 101 66.9 36 10.8 
cariprazine (1.5) 145 93 64.1 36.8 9.6 
cariprazine (3.0) 146 107 73.3 37.1 10.4 
cariprazine (4.5) 147 103 70.1 35.8 10.8 
risperidone (4.0) 140 98 70.0 36.5 11.1 
Durgam 
2015a [19] 
U.S, Russia & 
India 
Double-blind, 
placebo-controlled bipolar I mania 3 
placebo 118 77 65.3 38.7 11.0 
cariprazine (3-12) 118 80 67.8 38 10.3 
Durgam 
2015b [21] 
U.S, Canada, 
Colombia, 
Russia & 
Ukraine 
Double-blind, 
placebo-controlled 
bipolar I 
depression 8 
placebo 148 59 39.6 43.6 12.0 
cariprazine (0.75) 143 52 35.5 40.1 11.2 
cariprazine (1.5) 147 55 37.0 40.9 11.4 
cariprazine (3.0) 146 58 39.7 42.8 10.8 
Durgam 
2015c [15] U.S 
Double-blind, 
placebo-controlled schizophrenia 6 
placebo 129 103 79.8 41.1 9.9 
cariprazine (1.5-4.5) 127 105 82.7 40.3 11.1 
cariprazine (6-12) 133 101 75.9 42.4 9.0 
Durgam 
2015d [17] 
U.S, Romania, 
Russia & 
Ukraine 
Double-blind, 
placebo- and 
active-controlled 
schizophrenia 6 
placebo 153 97 63.4 38.2 11.3 
cariprazine (3) 155 99 63.9 37.9 10.6 
cariprazine (6) 157 100 63.7 38.6 10.6 
aripiprazole (10) 152 94 61.8 39.3 10.8 
Kane 2015 
[14] 
U.S, India, 
Colombia & 
South Africa 
Double-blind, 
placebo-controlled schizophrenia 6 
placebo 147 110 74.8 36.7 11.3 
cariprazine (3-6) 151 118 78.1 36.6 10.5 
cariprazine (9-12) 148 113 76.4 35.5 9.3 
Sachs 
2015 [18] U.S & India 
Double-blind, 
placebo-controlled bipolar I mania 3 
placebo 154 95 61.7 36.7 11.8 
cariprazine (3-12) 158 105 66.5 35.8 11.4 
Durgam 
2016. [22] U.S & Europe 
Double-blind, 
placebo-controlled 
major depressive 
disorder 8 
placebo, 
antidepressants 266 76 28.6 46.4 11.6 
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cariprazine (1-2), 
antidepressant 273 86 31.5 45.5 11.9 
cariprazine (2-4.5), 
antidepressant 273 72 26.4 45.1 11.4 
463 
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Table 2 Primary tolerability/safety outcomes of included RCTs 464 
Outcome No. of 
studies 
RR/Mean 
difference# 
(95%CI) 
Heterogeneity 
(95%PI) 
Discontinuation due to AEs 9 1.13 (0.77, 
1.66) 
P=0.07, I2=71% 
(0.32, 3.93) 
EPS-related 
outcomes 
Discontinuation 
due to EPS-
related TEAE 
5 3.31 (1.06, 
10.32) 
P=0.68, I2=0% 
(0.52, 21.00) 
Discontinuation 
due to akathisia 
4 8.71 (2.08, 
36.49) 
P=0.95, I2=0% 
(NA) 
Akathisia 9 3.92 (2.83, 
5.43) 
P=0.31, I2=11% 
(2.12, 7.25) 
Tremor 7 2.41 (1.52, 
3.79) 
P=0.31, I2=16% 
(1.01, 5.75) 
Restlessness 7 2.17 (1.38, 
3.40) 
P=0.27, I2=21% 
(0.85, 5.54) 
BARS, mean 
change 
5 0.32 (0.21, 
0.43) 
P=0.04, I2=60% 
(-0.04, 0.68) 
SAS, mean 
change 
5 0.45 (0.27, 
0.64) 
P=0.02, I2=65% 
(-0.18, 1.08) 
AIMS, mean 
change 
5 0.04 (-0.05, 
0.13) 
P=0.003, 
I2=75% (-0.31, 
0.39) 
Metabolic 
outcomes 
Body weight (kg) 9 0.61 (0.39, 
0.82) 
P=0.07, I2=46% 
(0.02, 1.20) 
Total cholesterol 
(mg/dL) 
9 -0.59 (-1.86, 
0.68) 
P=0.34, I2=12% 
(-3.00, 1.82) 
LDL (mg/dL) 9 -1.61 (-3.31, 
0.09) 
P=0.11, I2=39% 
(-5.65, 2.43) 
HDL (mg/dL) 9 0.02 (-0.06, 
0.10) 
P=0.50, I2=0% 
(-0.08, 0.12) 
Triglycerides 
(mg/dL) 
9 -0.04 (-0.25, 
0.16) 
P=0.80, I2=0% 
(-0.29, 0.21) 
Fasting glucose 
(mg/dL) 
9 1.31 (-0.19, 
2.82) 
P=0.02, I2=57% 
(-2.74, 5.36) 
PCS change in 
glucose*  
3 1.38 (0.47, 
4.08) 
P=0.38, I2=0% 
(NA) 
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Prolactin (ng/mL)  7 -0.53 (-3.30, 
2.23) 
P<0.001, 
I2=75% (-9.11, 
8.05) 
Cardiovascular 
outcomes  
Orthostatic 
hypotension  
7 0.93 (0.76, 
1.13) 
P=0.74, I2=0% 
(0.72, 1.21) 
SBP (mmHg) 9 0.83 (0.02, 
1.65) 
P=0.17, I2=31% 
(-1.05, 2.71) 
DBP (mmHg) 9 0.68 (0.04, 
1.32) 
P=0.15, I2=34% 
(-0.86, 2.22) 
Creatine kinase 
(U/L) 
4 17.49 (1.63, 
33.35) 
P=0.60, I2=0% 
(NA) 
 465 
# Results underlined were mean difference. 466 
Abbreviations: RR, relative risk; CI, confidence interval; PI, prediction interval; EPS, 467 
extrapyramidal side effects; AE, adverse events; AIMS, Abnormal Involuntary 468 
Movement Scale; SAE, serious adverse events; TEAE, treatment-emergent adverse 469 
events; BARS, Barnes Akathisia Rating Scale; SAS, Simpson-Angus Scale; LDL, low-470 
density lipoprotein; HDL, high-density lipoprotein; PCS, potentially clinically 471 
significant; SBP, systolic blood pressure; DBP, diastolic blood pressure; NA, not 472 
applicable. 473 
* PCS change in fasting glucose was defined as the shift from normal glucose levels 474 
(<100 mg/dL) at baseline to high glucose levels (≥126 mg/dL) at the end of treatment.475 
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